Skip to main content
Christopher Shaw

Professor Christopher Shaw MD, FRACP, FRCP (Hon), FMedSci, FANA, FK

Professor of Neurology and Neurogenetics

Research interests

  • Neuroscience

Contact details

Biography

I am a Professor of Neurology & Neurogenetics at the IoPPN and Director of The Maurice Wohl Clinical Neuroscience Institute. I am a Group Leader at UK DRI at King's and the former Director (2017-2022). My research group focuses on frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) with two main objectives:

  1. To develop novel AAV-based gene therapy therapeutic approaches. Optimising AAV9 vectors for gene delivery into the CNS from preclinical experiments in cells and rodents up to first-in-human experimental medicine studies.
  2. To map TDP-43 proteostasis in vitro using human iPSc-derived neurons: phenotypic analyses including transcriptomics, proteomics and high-content imaging in cultured motor neurons – including patient-derived iPSC and isogenic lines generated by genome editing with CRISPR/Cas9.

Please see my Research Staff Profile  for more detail.

Key Collaborators:

  • Professor Ammar Al-Chalabi, King's College London
  • Dr Robert H Brown Jr, University of Massachusetts
  • Professor John Landers, University of Massachusetts
  • Professor Siddarthan Chandran, University of Edinburgh

News

King's spinout to develop ground-breaking neurodegenerative gene therapy

AviadoBio is an exciting new spin-out company founded by King’s College London researchers Professor Christopher Shaw, Dr Youn Bok Lee and Dr Do Young Lee

Chris Shaw brain

News

King's spinout to develop ground-breaking neurodegenerative gene therapy

AviadoBio is an exciting new spin-out company founded by King’s College London researchers Professor Christopher Shaw, Dr Youn Bok Lee and Dr Do Young Lee

Chris Shaw brain